Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients

This article summarizes the results of the quality controls on 54 batches, to demonstrate the feasibility of producing a therapeutic cell-based vaccine via a well-controlled Good Manufacturing Practices (GMP)-compliant production process. The findings may be of scientific interest to those working in the field of preparation of GMP-compliant products for cell-therapy applications.

Source: Stem Cells Translational Medicine - September 17, 2015 Category: Stem Cells Authors: Nava, S., Lisini, D., Pogliani, S., Dossena, M., Bersano, A., Pellegatta, S., Parati, E., Finocchiaro, G., Frigerio, S. Tags: Standards, Policies, Protocols, and Regulations for Cell-Based Therapies, Mesenchymal Stem Cells Source Type: research